Text Size

12 Weeks Treatement With 3 Different Doses of BI 10773 in Type 2 Diabetic Patients

This study has been completed.
Sponsor:
Information provided by:
Boehringer Ingelheim Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00789035
First received: October 13, 2008
Last updated: October 12, 2009
Last verified: October 2009
History of Changes
  Purpose

The objective is to investigate the efficacy, safety and pharmacokinetics of three different doses of BI 10773 compared to placebo given for 12 weeks in patients with type 2 diabetes mellitus with insufficient glycemic control. In addition an open-label metformin arm will be assessed


Condition Intervention Phase
Diabetes Mellitus, Type 2
 Drug: BI 10773
Drug: placebo
Drug: metformin
 Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Official Title: A Phase IIb, Randomized, Parallel Group Safety, Efficacy, and Pharmacokinetics Study of BI 10773 (5 mg, 10 mg and 25 mg) Administered Orally Once Daily Over 12 Weeks Compared Double Blind to Placebo, as Monotherapy, With an Additional Open-label Metformin Arm in Type 2 Diabetic Patients With Insufficient Glycemic Control

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Boehringer Ingelheim Pharmaceuticals:

Primary Outcome Measures:
  • The primary endpoint is change in HbA1c from baseline after 12 weeks of treatment [ Time Frame: 12 weeks ]

Secondary Outcome Measures:
  • The main secondary endpoints are: 1. Change in FPG from baseline through 12 weeks of treatment 2. Change in HbA1c from baseline over time 3. Pharmocokinetics of BI 10773 [ Time Frame: 12 weeks ]

Enrollment: 408
Study Start Date: October 2008
Primary Completion Date: October 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male and female patients with a diagnosis of type 2 diabetes mellitus
  • HbA1c between 7% and 10%
  • Age between 18 and 80 years
  • BMI less than 40 kg/m2
  • Signed and dated informed consent prior to admission to the study in accordance with GCP and local legislation

Exclusion Criteria:

  1. Myocardial infarction, stroke or TIA within 6 months prior to informed consent
  2. Impaired hepatic function
  3. Renal insufficiency or impaired renal function
  4. Disease of central nervous system, or psychiatric disorders or clinically relevant neurologic disorders that may interfere with trial participation
  5. Chronic or clinically relevant acute infections
  6. Current or chronic urogenital tract infection determined by medical history
  7. History of clinically relevant allergy/hypersensitivity
  8. Treatment with glitazones, GLP-1 analogues or insulin within 3 months prior to informed consent
  9. Treatment with anti obesity drugs
  10. Current treatment with systemic steroids
  11. Alcohol abuse
  12. Treatment with an investigational drug within 2 months prior to informed consent
  13. Intolerance to metfomin
  14. Dehydration
  15. Unstable or acute CHF
  16. Acute or chronic acidosis
  17. Hereditary galactose intolerance
  18. Woman of child bearing potential who are nursing or pregnant or not practicing an acceptable method of birth control
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00789035

  Show 74 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim Pharmaceuticals
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim Pharmaceuticals
  More Information

No publications provided

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00789035     History of Changes
Other Study ID Numbers: 1245.9, EudraCT No 2008-000640-14
Study First Received: October 13, 2008
Last Updated: October 12, 2009
Health Authority: Argentina: A.N.M.A.T. (National Administration of Medications, Food and Medical Technology)
Croatia: Croatian Institute for Medicines Control, HR-10000 Zagreb
Estonia: State Agency of Medicines, EE-5041Tartu
Germany: Federal Institute for Drugs and Medical Devices
Italy: Comitato per la Sperimentazione Clinica dei Medicinali Azienda Ospedaliero-Universitaria Pisana
Korea, Republic of: Korea Food and Drug Administration (KFDA)
Lithuania: State Medicines Control Agency, LT-01132 Vilnius
Romania: National Medicines Agency, Bucharest
Russia: Ministry of Healthcare and Social Development of Russian Federation, Moscow
Slovakia: SUKL (state institute for drug control), SK-825 08 Bratislava 26
Sweden: Medical Products Agency, Box 26, 751 03 Uppsala, Sweden Regional Ethical Review Board of Stockholm, PO Box 289, SE-171 77 Stockholm, Sweden.
Taiwan: Department of Health, Executive Yuan, Taiwan
Ukraine: Ministry of Health Care of Ukraine (MoH of Ukraine)

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
 Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 19, 2013